LLYEli Lilly and Company

LLY Stock Price, Valuation & Chart | Eli Lilly and Company

Compare

$1115.25-7.75 (-0.69%)

At close · 11 Sept 2026, 07:59 pm

Sector: Healthcare Industry: Drug Manufacturers - General LLY intrinsic value

Overview Financials Dividends Ratios

LLY Historical price chart

LLY Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization1.05T

PE Ratio35.42

EPS31.49

Trading Volume1.83M

Today's High/Low1131.4/1113.2

Dividend Yield0.60

52 Week High/Low1292.65/712.05

Shares Outstanding941.74M

LLY Financial Statement

LLY Analyst ratings

LLY Analysis & performance metrics

LLY Company profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog…

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2…

LLY Management team

Name

Position

Daniel M. Skovronsky M.D., Ph.D.

Chief Scientific & Product Officer and President of Lilly Research Laboratories

Jacob S. Van Naarden

Executive Vice President & President of Lilly Oncology

Eric Dozier

Executive Vice President & Chief People Officer

Jeffrey N. Simmons

Senior Vice President & President of Elanco Animal Health

Lucas E. MontarceCFO

Executive Vice President & Chief Financial Officer

Donald A. Zakrowski

Senior Vice President of Finance & Chief Accounting Officer

David A. RicksCEO

Chairman, Chief Executive Officer & President

Anat Hakim J.D.

Executive Vice President, General Counsel & Secretary

Name

Position

Daniel M. Skovronsky M.D., Ph.D.

Chief Scientific & Product Officer and President of Lilly Research Laboratories

Jacob S. Van Naarden

Executive Vice President & President of Lilly Oncology

Eric Dozier

Executive Vice President & Chief People Officer

Jeffrey N. Simmons

Senior Vice President & President of Elanco Animal Health

Lucas E. MontarceCFO

Executive Vice President & Chief Financial Officer

Donald A. Zakrowski

Senior Vice President of Finance & Chief Accounting Officer

David A. RicksCEO

Chairman, Chief Executive Officer & President

Anat Hakim J.D.

Executive Vice President, General Counsel & Secretary

Management Team

Daniel M. Skovronsky M.D., Ph.D.

Chief Scientific & Product Officer and President of Lilly Research Laboratories

Jacob S. Van Naarden

Executive Vice President & President of Lilly Oncology

Eric Dozier

Executive Vice President & Chief People Officer

Jeffrey N. Simmons

Senior Vice President & President of Elanco Animal Health

Lucas E. MontarceCFO

Executive Vice President & Chief Financial Officer

Donald A. Zakrowski

Senior Vice President of Finance & Chief Accounting Officer

David A. RicksCEO

Chairman, Chief Executive Officer & President

Anat Hakim J.D.

Executive Vice President, General Counsel & Secretary

Management

Daniel M. Skovronsky M.D., Ph.D.

Chief Scientific & Product Officer and President of Lilly Research Laboratories

Jacob S. Van Naarden

Executive Vice President & President of Lilly Oncology

Eric Dozier

Executive Vice President & Chief People Officer

Jeffrey N. Simmons

Senior Vice President & President of Elanco Animal Health

Lucas E. MontarceCFO

Executive Vice President & Chief Financial Officer

Donald A. Zakrowski

Senior Vice President of Finance & Chief Accounting Officer

David A. RicksCEO

Chairman, Chief Executive Officer & President

Anat Hakim J.D.

Executive Vice President, General Counsel & Secretary

Total 8 executives

LLY Frequently asked questions

What is Eli Lilly and Company (LLY) Stock Price?

Current stock price of Eli Lilly and Company (LLY) stock is $1115.25. The stock price is -0.69% lower in the session. The intraday range can be seen from this page. Volume of Eli Lilly and Company (LLY) stock is 1.83M.

Last updated at 11 Sept 2026, 07:59 pm.

Why is the Eli Lilly and Company (LLY) stock price going up or down today?

The stock price of Eli Lilly and Company (LLY) can change with earnings, company news, and overall market sentiment. Eli Lilly and Company operates in the Healthcare / Drug Manufacturers - General market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Eli Lilly and Company stock expensive at its current price?

Whether Eli Lilly and Company looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for LLY on this page is 35.42. EPS on this page is 31.49. Compare those figures with peers and growth expectations before deciding if the current Eli Lilly and Company price is justified.

How has the stock price of Eli Lilly and Company (LLY) performed historically?

Historical performance for Eli Lilly and Company (LLY) is shown on the price chart on this page. Review multi-period moves alongside volume to see how LLY reacted to past earnings and market events.

Should I buy Eli Lilly and Company (LLY) stock, at this price?

Buying Eli Lilly and Company (LLY) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.